Canada Spends Logo

Explorez notre analyse du budget 2026

Grant: Project Grant

University of Calgary

$100,000.00

Molecular mechanisms underlying the enhanced efficacy of inhaled corticosteroid/long-acting beta2-adrenoceptor agonist combinations used in asthma

EF 2016-17

Résumé
Asthma is a chronic inflammatory disease, characterised by intermittent airways constriction and occurs in up to 10% of individuals. Regular inhaled glucocorticoids (GCs) are clinically referred to as inhaled corticosteroid (ICS) and dampen lung inflammation to control mild to moderate asthma. However, more severe disease and asthma exacerbations are poorly controlled by ICS. Clinical guidelines therefore recommend the addition of a long-acting beta2-adrenoceptor agonist (LABA) as these drugs enhance the effectiveness of the ICS to a level that is not achieved by increasing the ICS dose. In particular, the glucocorticoid receptor (GR), the protein target by which GCs act, is responsible for modulating gene expression and this mediates the beneficial effects in asthma. With a LABA, combinatorial effects between GC- and LABA-activated pathways enhance the effectiveness of ICS/LABA therapy. However, the underlying molecular basis is not established. The current proposal elucidates mechanisms underlying this clinically important effect. While this may represent sufficient scientific justification, it is salient that the pharmaceutical sector is testing novel drugs, often called selective GR modulators that activate GR in ways that are different to conventional GCs. These GR modulators enhance some aspects of GR function relative to other activities with a view to improving the clinical efficacy of GR-based therapies. However, it is important to stress that we do not know which aspects of GR function are required for synergy with LABA. There is therefore a considerable risk of failing to identify GR modulators that will most effectively synergise with LABAs. This will preclude maximising the benefit of future combination therapies. The current project addresses this key knowledge gap by identifying mechanisms of GR action that synergise with LABA. Effective knowledge translation of our data will help guide the discovery of improved combination treatments for asthma.
Programme
Project Grant
Bénéficiaire
Emplacement
Alberta, Canada
Type de bénéficiaire
Academia
Type
Grant
Source
CIHR Funding Decisions Database

Tel que publié

Id
366550
Name
Newton Robert
Region
Alberta
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Circulatory and Respiratory Health
Theme2
Biomedical
Prcname2
Project Grant Competition
Projecttitle
Molecular mechanisms underlying the enhanced efficacy of inhaled corticosteroid/long-acting beta2-adrenoceptor agonist combinations used in asthma
Programtype2
Operating Grants
Orgnameinp2
University of Calgary
Cihramount2
$100,000
Cihrequipment2
$0
Programname2
Project Grant
Keyworddelim
Gene Expression; Glucocorticoids / Corticosteroids; Long-Acting Beta2-Agonists; Regulation; Transcriptional Control
Abstract
Asthma is a chronic inflammatory disease, characterised by intermittent airways constriction and occurs in up to 10% of individuals. Regular inhaled glucocorticoids (GCs) are clinically referred to as inhaled corticosteroid (ICS) and dampen lung inflammation to control mild to moderate asthma. However, more severe disease and asthma exacerbations are poorly controlled by ICS. Clinical guidelines therefore recommend the addition of a long-acting beta2-adrenoceptor agonist (LABA) as these drugs enhance the effectiveness of the ICS to a level that is not achieved by increasing the ICS dose. In particular, the glucocorticoid receptor (GR), the protein target by which GCs act, is responsible for modulating gene expression and this mediates the beneficial effects in asthma. With a LABA, combinatorial effects between GC- and LABA-activated pathways enhance the effectiveness of ICS/LABA therapy. However, the underlying molecular basis is not established. The current proposal elucidates mechanisms underlying this clinically important effect. While this may represent sufficient scientific justification, it is salient that the pharmaceutical sector is testing novel drugs, often called selective GR modulators that activate GR in ways that are different to conventional GCs. These GR modulators enhance some aspects of GR function relative to other activities with a view to improving the clinical efficacy of GR-based therapies. However, it is important to stress that we do not know which aspects of GR function are required for synergy with LABA. There is therefore a considerable risk of failing to identify GR modulators that will most effectively synergise with LABAs. This will preclude maximising the benefit of future combination therapies. The current project addresses this key knowledge gap by identifying mechanisms of GR action that synergise with LABA. Effective knowledge translation of our data will help guide the discovery of improved combination treatments for asthma.
Competitiondate
201611
Approvedterm2
1 yr 0 mth
Pinamesdelim
Newton, Robert
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $100,000~ $0~